MX340217B - Metodo para el tratamietno y bioensayo que involucra el factor de inhibicion de migracion de macrofagos (mif), como un factor de depresion del miocardio, derivado del corazon. - Google Patents
Metodo para el tratamietno y bioensayo que involucra el factor de inhibicion de migracion de macrofagos (mif), como un factor de depresion del miocardio, derivado del corazon.Info
- Publication number
- MX340217B MX340217B MX2011013436A MX2011013436A MX340217B MX 340217 B MX340217 B MX 340217B MX 2011013436 A MX2011013436 A MX 2011013436A MX 2011013436 A MX2011013436 A MX 2011013436A MX 340217 B MX340217 B MX 340217B
- Authority
- MX
- Mexico
- Prior art keywords
- mif
- factor
- cardiac
- effective amount
- therapeutically effective
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica, la cual incluye una cantidad efectiva terapéuticamente de al menos un anticuerpo anti-MIF; y al menos un portador aceptable. Otra modalidad de la presente invención se refiere a una composición farmacéutica, la cual incluye una cantidad efectiva terapéuticamente de al menos un anticuerpo anti-CD74; y al menos un portador aceptable farmacéuticamente. Otra modalidad de la presente invención se refiere a otra composición farmacéutica, la cual incluye una cantidad efectiva terapéuticamente de al menos un anticuerpo anti- TNFR, una cantidad efectiva terapéuticamente de al menos un anticuerpo anti-MIF, y al menos un portador aceptable farmacéuticamente. Otras modalidades de la presente invención se refieren a métodos para tratar o prevenir una disfunción cardiaca, cardiodepresión, disfunción cardiaca asociada con lesiones por quemaduras, mejorar la función cardiaca en un sujeto en seguida de un infarto agudo al miocardio, e identificar un inhibidor del Factor Inhibidor de la Migración de Macrófagos (MIF).
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49865903P | 2003-08-29 | 2003-08-29 | |
| US54705404P | 2004-02-25 | 2004-02-25 | |
| US54705904P | 2004-02-25 | 2004-02-25 | |
| US54705604P | 2004-02-25 | 2004-02-25 | |
| US54705704P | 2004-02-25 | 2004-02-25 | |
| US55644004P | 2004-03-26 | 2004-03-26 | |
| US10/927,494 US20050202010A1 (en) | 2003-08-29 | 2004-08-27 | Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX340217B true MX340217B (es) | 2016-06-30 |
Family
ID=34280266
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06001828A MXPA06001828A (es) | 2003-08-29 | 2004-08-30 | Metodo para el tratamiento y bioensayo que involucra el factor de inhibicion de migracion de macrofagos ("mif"), como un factor de depresion del miocardio, derivado del corazon. |
| MX2011013436A MX340217B (es) | 2003-08-29 | 2006-02-16 | Metodo para el tratamietno y bioensayo que involucra el factor de inhibicion de migracion de macrofagos (mif), como un factor de depresion del miocardio, derivado del corazon. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06001828A MXPA06001828A (es) | 2003-08-29 | 2004-08-30 | Metodo para el tratamiento y bioensayo que involucra el factor de inhibicion de migracion de macrofagos ("mif"), como un factor de depresion del miocardio, derivado del corazon. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20050202010A1 (es) |
| EP (2) | EP1658037B1 (es) |
| JP (3) | JP4891769B2 (es) |
| CN (2) | CN102499984B (es) |
| AU (1) | AU2004268017B2 (es) |
| BR (1) | BRPI0413404A (es) |
| CA (1) | CA2537928C (es) |
| CY (1) | CY1117925T1 (es) |
| DK (1) | DK1658037T3 (es) |
| ES (1) | ES2599032T3 (es) |
| HU (1) | HUE029888T2 (es) |
| MX (2) | MXPA06001828A (es) |
| PL (1) | PL1658037T3 (es) |
| PT (1) | PT1658037T (es) |
| WO (1) | WO2005020919A2 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050202010A1 (en) | 2003-08-29 | 2005-09-15 | Giroir Brett P. | Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor |
| AU2005228417A1 (en) * | 2004-03-26 | 2005-10-13 | Cytokine Pharmasciences, Inc. | Compouns, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor |
| WO2006063150A2 (en) * | 2004-12-08 | 2006-06-15 | Immunomedics, Inc. | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
| WO2006116688A2 (en) * | 2005-04-26 | 2006-11-02 | Yale University | Mif agonists and antagonists and therapeutic uses thereof |
| US20110044988A1 (en) * | 2008-03-20 | 2011-02-24 | Carolus Therpeutics, Inc. | Methods of treatment using anti-mif antibodies |
| CA2716628A1 (en) * | 2008-03-24 | 2009-10-01 | Carolus Therapeutics, Inc. | Methods and compositions for treating atherosclerosis and related conditions |
| US20100183598A1 (en) * | 2008-11-12 | 2010-07-22 | Carolus Therapeutics, Inc. | Methods of treating cardiovascular disorders |
| WO2010065491A2 (en) * | 2008-12-01 | 2010-06-10 | Carolus Therapeutics, Inc. | Methods of treating inflammatory disorders |
| JP2014526886A (ja) | 2011-07-15 | 2014-10-09 | モルフォシス・アー・ゲー | マクロファージ遊走阻止因子（ｍｉｆ）とｄ−ドーパクロームトートメラーゼ（ｄ−ｄｔ）に交差反応性がある抗体 |
| CN103988076A (zh) * | 2011-08-12 | 2014-08-13 | 阿尔弗雷德医疗集团 | 包括测量巨噬细胞移动抑制因子（mif）的血浆浓度的诊断、预后或治疗急性冠状动脉综合征（acs）的方法 |
| JP2014530360A (ja) | 2011-10-07 | 2014-11-17 | バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ | 診断マーカーとしてのｏｘＭＩＦ |
| US20150309012A1 (en) * | 2012-12-07 | 2015-10-29 | Baxter International Inc. | Anti-mif antibody cell migration assay |
| CN105087610A (zh) * | 2015-09-11 | 2015-11-25 | 中国科学院海洋研究所 | 文蛤巨噬细胞迁移抑制因子基因及其编码蛋白和应用 |
| JP2018007029A (ja) * | 2016-07-01 | 2018-01-11 | 株式会社村田製作所 | バイアス回路 |
| JP7549537B2 (ja) * | 2018-08-30 | 2024-09-11 | ザルトリウス バイオアナリティカル インストゥルメンツ， インコーポレイテッド | 単一サンプル中の低濃度及び高濃度タンパク質の濃度を決定する方法 |
| WO2022235865A1 (en) * | 2021-05-06 | 2022-11-10 | Abbott Molecular Inc. | Compositions and methods for simple sample extraction |
| CN114288387A (zh) * | 2022-02-17 | 2022-04-08 | 重庆医科大学 | Humanin衍生物HNG在制备治疗心衰药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6030615A (en) * | 1993-05-17 | 2000-02-29 | The Picower Institute For Medical Research | Combination method for treating diseases caused by cytokine-mediated toxicity |
| US6492428B1 (en) | 2000-07-26 | 2002-12-10 | The Picower Institute For Medical Research | Compounds having MIF antagonist activity |
| US6420188B1 (en) | 1996-02-16 | 2002-07-16 | The Picower Institute For Medical Research | Screening assay for the identification of inhibitors for macrophage migration inhibitory factor |
| US6228359B1 (en) * | 1997-11-05 | 2001-05-08 | University Of Southern California | Use of cytokines and mitogens to inhibit pathological immune responses |
| AU1235601A (en) | 1999-10-29 | 2001-05-14 | Cytokine Pharmasciences, Inc. | Compounds having mif antagonist activity |
| US6268151B1 (en) | 2000-01-20 | 2001-07-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of macrophage migration inhibitory factor expression |
| WO2001064749A2 (en) * | 2000-02-28 | 2001-09-07 | Idec Pharmaceuticals Corporation | Method for preparing anti-mif antibodies |
| ATE473294T1 (de) * | 2001-03-29 | 2010-07-15 | Cytokine Pharmasciences Inc | Verfahren und zusammensetzungen zur verwendung von mhc-klasse ii-invariante-kette-polypeptid als rezeptor für makrophagenwanderung-hemmfaktor |
| JP4410553B2 (ja) * | 2001-06-08 | 2010-02-03 | サイトカイン・ファーマサイエンシズ・インコーポレーテッド | Ｍｉｆアンタゴニスト活性を有するイソオキサゾリン化合物 |
| US20050202010A1 (en) | 2003-08-29 | 2005-09-15 | Giroir Brett P. | Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor |
-
2004
- 2004-08-27 US US10/927,494 patent/US20050202010A1/en not_active Abandoned
- 2004-08-30 EP EP04782427.1A patent/EP1658037B1/en not_active Expired - Lifetime
- 2004-08-30 CN CN201110370579.7A patent/CN102499984B/zh not_active Expired - Lifetime
- 2004-08-30 CN CN2004800247776A patent/CN1972713B/zh not_active Expired - Lifetime
- 2004-08-30 ES ES04782427.1T patent/ES2599032T3/es not_active Expired - Lifetime
- 2004-08-30 AU AU2004268017A patent/AU2004268017B2/en not_active Expired
- 2004-08-30 PT PT47824271T patent/PT1658037T/pt unknown
- 2004-08-30 BR BRPI0413404-4A patent/BRPI0413404A/pt not_active Application Discontinuation
- 2004-08-30 EP EP16170803.7A patent/EP3078386A3/en not_active Withdrawn
- 2004-08-30 PL PL04782427T patent/PL1658037T3/pl unknown
- 2004-08-30 MX MXPA06001828A patent/MXPA06001828A/es active IP Right Grant
- 2004-08-30 DK DK04782427.1T patent/DK1658037T3/en active
- 2004-08-30 JP JP2006524893A patent/JP4891769B2/ja not_active Expired - Lifetime
- 2004-08-30 CA CA2537928A patent/CA2537928C/en not_active Expired - Lifetime
- 2004-08-30 HU HUE04782427A patent/HUE029888T2/en unknown
- 2004-08-30 WO PCT/US2004/027945 patent/WO2005020919A2/en active Application Filing
-
2006
- 2006-02-16 MX MX2011013436A patent/MX340217B/es unknown
-
2007
- 2007-10-31 US US11/932,909 patent/US8747843B2/en active Active
-
2010
- 2010-02-24 JP JP2010039451A patent/JP5905659B2/ja not_active Expired - Lifetime
-
2011
- 2011-06-15 JP JP2011133728A patent/JP2011251966A/ja active Pending
-
2014
- 2014-05-19 US US14/281,870 patent/US20150017179A1/en not_active Abandoned
-
2016
- 2016-08-25 CY CY20161100837T patent/CY1117925T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011251966A (ja) | 2011-12-15 |
| CA2537928C (en) | 2015-05-05 |
| CN1972713B (zh) | 2012-02-29 |
| JP4891769B2 (ja) | 2012-03-07 |
| US20150017179A1 (en) | 2015-01-15 |
| WO2005020919A2 (en) | 2005-03-10 |
| CN1972713A (zh) | 2007-05-30 |
| JP2010159267A (ja) | 2010-07-22 |
| JP2007504158A (ja) | 2007-03-01 |
| EP1658037B1 (en) | 2016-05-25 |
| AU2004268017A2 (en) | 2005-03-10 |
| ES2599032T3 (es) | 2017-01-31 |
| MXPA06001828A (es) | 2007-05-23 |
| PL1658037T3 (pl) | 2017-08-31 |
| US8747843B2 (en) | 2014-06-10 |
| WO2005020919A3 (en) | 2006-11-30 |
| US20050202010A1 (en) | 2005-09-15 |
| HUE029888T2 (en) | 2017-04-28 |
| EP3078386A3 (en) | 2017-01-11 |
| AU2004268017A1 (en) | 2005-03-10 |
| CN102499984A (zh) | 2012-06-20 |
| CN102499984B (zh) | 2015-02-18 |
| AU2004268017B2 (en) | 2011-03-17 |
| DK1658037T3 (en) | 2016-08-29 |
| CY1117925T1 (el) | 2017-05-17 |
| BRPI0413404A (pt) | 2006-10-17 |
| CA2537928A1 (en) | 2005-03-10 |
| EP3078386A2 (en) | 2016-10-12 |
| JP5905659B2 (ja) | 2016-04-20 |
| PT1658037T (pt) | 2016-08-30 |
| US20080260723A1 (en) | 2008-10-23 |
| EP1658037A4 (en) | 2008-09-10 |
| EP1658037A2 (en) | 2006-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX340217B (es) | Metodo para el tratamietno y bioensayo que involucra el factor de inhibicion de migracion de macrofagos (mif), como un factor de depresion del miocardio, derivado del corazon. | |
| TW200716081A (en) | Combination of organic compounds | |
| CY1119389T1 (el) | Μεθοδος για τη θεραπευτικη αγωγη της πολλαπλης σκληρυνσης | |
| EP3530288A3 (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| ATE530577T1 (de) | Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren | |
| PT97615A (pt) | Metodo para atingir um efeito terapeutico sinergistico com composicoes terapeuticas contendo pelo menos dois agentes terapeuticos seleccionados a partir de um inibidor de renina, um inibidor de enzima de conversao de angiotensina i e um antagonista de angiotensina ii | |
| CO5670356A2 (es) | Programa de dosificaicon para un nuevo agente anticanceroso | |
| MXPA05007379A (es) | Metodo para tratar nauseas, vomito, esfuerzo por vomitar o cualquier combinacion de los mismos. | |
| AU2003218215A1 (en) | Azolylaminoazines as inhibitors of protein kinases | |
| HK1091127A1 (en) | Compounds and methods for downregulating the effects of tgf-beta | |
| WO2007056324A3 (en) | Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent | |
| WO2006048877A3 (en) | Treatment of b-cell malignancies with fgfr3 inhibitors | |
| SG156681A1 (en) | Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure | |
| EA200400734A1 (ru) | Способ и композиция для потенциирования действия опиатного анальгетика | |
| DE60108489D1 (de) | Kombinationstherapien mit gefässschädigender aktivität | |
| AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
| WO2003092606A3 (en) | Cholinesterase inhibitors to prevent injuries caused by chemicals | |
| WO2001041754A8 (en) | Inhibitors of collagen-induced platelet aggregation | |
| HUP9801022A2 (hu) | Eljárás aldóz reduktáz inhibítor alkalmazása diabetikus szívizom-betegség megelőzésére vagy megfordítására | |
| ES2184341T3 (es) | Un metodo para la prevencion y el tratamiento de la disfuncion del miocardio. | |
| AR032422A1 (es) | Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca | |
| UY26171A1 (es) | Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía | |
| EA200400302A1 (ru) | Способ лечения первичной бессонницы | |
| DE60309465D1 (de) | Behandlung oder prävention von urogenitaler atrophie und deren symptomen bei frauen | |
| WO2003105891A3 (en) | USE OF HEC1 ANTAGONISTS IN THE TREATMENT OF PROLIFERATIVE DISORDERS AND CANCERS |